Prospective trial assesses disease-modifying therapies' effects on cognition and clinical outcomes in multiple sclerosis patients, indicating significant differences between populations.
To assess the effects of DMTs on cognition, retinal integrity, fatigue, and EDSS, over 24 months in African American and non-African American patients with relapsing MS.
No takes yet. Share an insight, caveat, or question.
Ropero et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: